RBC upgrades Hikma Pharmaceuticals to 'outperform'
Analysts at RBC Capital Markets upgraded from 'sector perform' to 'outperform' on Tuesday as it took a look at the wider European pharmaceutical and biotechnology sector.
RBC said after "a robust rebound" for Hikma's Generics division in 2023, growth has been slower in 2024 due to "higher payaways on sodium oxybate".
However, it still expects Hikma to return to mid-high single-digit growth CER, with "notable opportunities" in its Injectables and Branded business segments.
The Canadian bank also noted that Hikma trades at a sector discount on PEG ratio and said, even if the multiple doesn't re-rate, the combination of high single-digit earnings growth and 3% dividend yield should support attractive shareholder returns.
"We value Hikma using an average of three approaches. Our PE sum-of-the-parts sets fair value at £22.71. A PEG ratio analysis (sector of 1.7x) suggests a lower valuation of £21.70, Finally, our DCF model (9% cost of equity and 1.5% terminal growth rate) suggests fair value at £26.76. The average of these approaches, rounded to the nearest 25.0p, sets our price target at £23.75, which implies over 20% upside," said RBC.
Reporting by Iain Gilbert at Sharecast.com
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.